AlkermesALKS
Recorded

Alkermes 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 4 minParticipants24

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Greetings, and welcome to the Alkermes third quarter 2026 financial results conference call. My name is Dylan, and I will be your Operator for today's call. All participant lines will be placed on mute to prevent background noise. If you should require Operator assistance during the call, please press star zero from your telephone keypad. Please note, this conference is being recorded. I will now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin.

Sandy CoombsSVP of Investor Relations and Corporate Affairs

Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended September 30, 2026. With me today are Blair Jackson, our Chief Executive Officer, Todd Nichols, our Chief Commercial Officer, and Joshua Reed, our Chief Financial Officer. A slide presentation, along with our press release, related financial tables, and reconciliations of the GAAP to non-GAAP financial measures that we will discuss today are available on the Investors section of alkermes.com. We believe the non-GAAP financial results, in conjunction with the GAAP results, are useful in understanding the ongoing economics of our business. Our discussions during this conference call will include forward-looking statements. Actual results could differ materially from these forward-looking statements.

Sandy CoombsSVP of Investor Relations and Corporate Affairs

Please see slide 2 of the accompanying presentation, our press release issued this morning, and our most recent annual report filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we will open the call for Q&A. I will now turn the call over to Blair for some opening remarks.

Blair JacksonCEO

Thank you, Sandy. Good morning, everyone. On my first quarterly call as CEO of Alkermes, I would like to start with a few thoughts on the opportunity ahead and the priorities that will guide us. We have a clear strategy and a strong foundation. Our focus now is on execution. That means advancing our pipeline with rigor and urgency, driving strong commercial and financial performance, and allocating capital thoughtfully to our highest value opportunities. Our commercial business is an important element of our strategy and provides a strong financial foundation to invest in innovation. Our greatest opportunity for growth and value creation lies in our pipeline, particularly our leadership in orexin research and the potential of our orexin development portfolio to yield important new treatment options in neuropsychiatry. I will discuss the significant momentum across our development pipeline in more detail following the discussion of the quarterly results.

Blair JacksonCEO

The combination of commercial strength, financial performance, and a differentiated pipeline positions Alkermes well for its next chapter and the potential for meaningful long-term value creation for shareholders. I am incredibly proud and honored to lead Alkermes at this important point in its evolution, and I am confident in our strategy, our people, and the opportunities ahead. With that, let's turn to the quarter, Todd.

Todd NicholsChief Commercial Officer

Thank you, Blair. Good morning, everyone. I am pleased to report that we delivered strong performance across our commercial portfolio in the third quarter, reflecting contributions across addiction, psychiatry, and sleep medicine. Our teams remain focused on driving demand, broadening patient access, and building on the opportunities across our four proprietary products. In the third quarter, net sales from our proprietary product portfolio increased 31% year over year to $417.3 million, reflecting the addition of LUMRYZ and continued demand growth across our established commercial portfolio. Starting with VIVITROL, net sales in the third quarter were $127.6 million. VIVITROL continued to see strong demand driven by penetration in the alcohol dependence market. Net sales also benefited from approximately $8 million in gross-to-net favorability, primarily driven by favorable patient mix. For the full year, we continue to expect VIVITROL net sales in the range of $460 million-$480 million.

Todd NicholsChief Commercial Officer

We remain confident in the strength and durability of our VIVITROL business and look forward to continuing our impact with this important medicine. Turning to our psychiatry franchise, third quarter net sales for ARISTADA product family were $103.9 million. ARISTADA continued to see demand growth driven by expansion in HCP adoption. Net sales also benefited from approximately $7 million of gross-to-net and inventory favorability. We are encouraged by ARISTADA's continued strong performance within this category. For the full year, we continue to expect ARISTADA net sales in the range of $365 million-$385 million. LYBALVI net sales were $95.9 million in the third quarter, with underlying TRX growth of 18% year over year, supported by new patient starts and broader prescriber adoption. Net sales also reflected approximately $2 million of inventory benefit.

Todd NicholsChief Commercial Officer

Last quarter, we implemented a strategic expansion of the LYBALVI market access profile that we believe will position LYBALVI for long-term growth. Access now stands at approximately 80% of covered lives, and as a result, we have already seen positive trends on volume demand and prescription fulfillment. As expected, gross-to-net adjustments were approximately 42% during the third quarter. For the full year, we continue to expect LYBALVI net sales in the range of $380 million-$400 million. Looking ahead to next year, we expect gross-to-net adjustments for LYBALVI to be in the 45% range. We expect the benefits of expanded payer access to be reflected first in prescription volume, which we expect will continue to grow nearly 20% year over year, with an acceleration in net sales growth expected to follow. Beyond 2027, we expect volume growth and net sales growth to track more closely together again.

Todd NicholsChief Commercial Officer

Turning to our sleep franchise. LUMRYZ net sales were $89.9 million in the third quarter. We reached approximately 4,100 patients on therapy at quarter end, reflecting strong underlying demand, broader prescriber adoption, and increased use among existing prescribers. Net sales also reflected the drawdown of approximately $7 million of inventory build that we highlighted in our second quarter results. Last month, we presented results from the positive phase III REVITALYZ study of LUMRYZ in idiopathic hypersomnia at the Sleep Europe meeting. IH is a fast-growing segment for the oxybate market. The REVITALYZ data will serve as the foundation for the sNDA submission for IH, with a potential launch in March 2028, if approved. IH represents an important potential growth opportunity for LUMRYZ, and we look forward to updating you on our progress.

Todd NicholsChief Commercial Officer

For the full year, we continue to expect total LUMRYZ net sales of $350 million-$370 million, of which Alkermes expects to record $315 million-$335 million, reflecting the mid-February close of the Avadel transaction. Supporting LUMRYZ, we have an established sleep medicine platform that includes an experienced commercial and medical organization with a deep understanding of the market dynamics and HCP and patient journeys. This platform provides a strong foundation to support the potential launch of alixorexton and our broader ambition to become leaders in sleep medicine across multiple treatment modalities. Across our proprietary portfolio, we expect net sales to be in the range of $400 million-$420 million in the fourth quarter. We are pleased with what we have accomplished so far this year and remain focused on delivering against our 2026 objectives.

Todd NicholsChief Commercial Officer

As we enter the final quarter, our priorities remain clear: drive demand for our medicines, expand patient access, and position our brands for continued growth. With that, I will pass the call to Joshua to review the financial results for the quarter.

Joshua ReedCFO

Thank you, Todd. We delivered solid financial results in the third quarter, supported by the strength of our commercial portfolio and disciplined management of the business. Through the first nine months of the year, our financial position has provided the flexibility to advance our strategic priorities and invest in key opportunities that we believe will support our future growth. During the quarter, we generated total revenues of $480.1 million. As Todd outlined, our portfolio of proprietary products generated net sales of $417.3 million. These results reflect contributions from all four of our proprietary products and positive underlying demand trends across the commercial business. Manufacturing and royalty revenues were $62.9 million for the quarter, including $29.5 million from VUMERITY and $26.4 million from the long-acting INVEGA products.

Joshua ReedCFO

Turning to expenses, cost of goods sold in the third quarter was $94.2 million, which includes the purchase price fair value accounting of LUMRYZ inventory that we described last quarter. This compared to $51.6 million in Q3 of the prior year. R&D expenses in the quarter were $121.1 million compared to $81.7 million in Q3 of the prior year, reflecting continued investment in our orexin development portfolio. Of note, our development activities during the quarter included the alixorexton phase III studies initiated earlier this year and clinical development activities to advance ALKS 7290 in ADHD and MDD, as well as ALKS 4510 in fatigue associated with Parkinson's disease or multiple sclerosis.

Joshua ReedCFO

SG&A expenses were $208.5 million for the quarter compared to $171.8 million in Q3 of the prior year, with the addition of the Avadel commercial infrastructure as the primary driver of the year-over-year change. During the quarter, we also recorded amortization of acquired intangible assets of $19.7 million and net interest expense of $21.1 million. In Q3, we recorded GAAP net income of $16.3 million and EBITDA of $63 million. Adjusted EBITDA was $120.1 million, which we believe provides a useful measure of the underlying cash-generating performance of the business during the quarter. From a balance sheet perspective, we entered the third quarter in a strong position with approximately $787.6 million in cash and total investments. For the year, we are reiterating our 2026 financial expectations provided in July across all line items.

Joshua ReedCFO

Our performance through the first nine months of the year positions us well to deliver against these expectations. Our 2026 financial performance and operating expenses reflect a number of Avadel transaction-related costs. As we look ahead to our 2027 operating expense profile, there are a few important dynamics to keep in mind, beginning with cost of goods sold. With the vast majority of the non-cash LUMRYZ inventory fair value step-up associated with the Avadel acquisition being recognized in 2026, we expect cost of goods sold to be lower in 2027, reflective of more normalized patterns. For SG&A, excluding the transaction-related costs recorded in early 2026, we expect a broadly similar expense profile for 2027. For R&D, our 2027 investment will reflect the growing number of programs across the portfolio and the broader level of clinical activity planned.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day